| 1 |
29360121 | Why does the Y326I mutant of monoamine oxidase B decompose an endogenous amphetamine at a slower rate than the wild type enzyme? Reaction step elucidated by multiscale molecular simulations. | 2018 Feb 7 |
1 |
| 2 |
18261369 | CYP-dependent metabolism of PF9601N, a new monoamine oxidase-B inhibitor, by C57BL/6 mouse and human liver microsomes. | 2007 |
2 |
| 3 |
16156677 | Alternatives to levodopa in the initial treatment of early Parkinson's disease. | 2005 |
1 |
| 4 |
10433493 | Relevance of benzyloxy group in 2-indolyl methylamines in the selective MAO-B inhibition. | 1999 Jun |
1 |
| 5 |
7618520 | Aliphatic propargylamines, a new series of potent selective, irreversible non-amphetamine-like MAO-B inhibitors. Their structures, function and pharmacological implications. | 1995 |
1 |
| 6 |
8363648 | Effect of structural modification of alkyl N-propargylamines on the selective inhibition of monoamine oxidase B activity. | 1993 Aug 17 |
1 |
| 7 |
3120270 | Selegiline in narcolepsy. | 1987 Oct |
1 |
| 8 |
6777463 | Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. | 1980 Nov |
1 |